BPC-157 vs TB-500: A Chemistry and Mechanism Comparison
By the TWO+DOS Research Team · Published 2026-08-12 · Reviewed 2026-08-13
For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic use.
BPC-157 and TB-500 are two synthetic peptides that appear together in laboratory research on tissue repair, and they are structurally unrelated. BPC-157 is a 15-residue sequence with no identified receptor. TB-500 is a 7-residue fragment of an endogenous protein whose molecular target, actin, has been resolved by crystallography.
The two are frequently discussed as a pair, which obscures how differently each one is characterized in the scientific record. This comparison covers what distinguishes them chemically, which molecular interactions the published literature has actually measured for each, and how each has been characterized analytically. It reports findings as the cited authors published them, in the model systems they used.
Chemical and physical properties of BPC-157 and TB-500
| BPC-157 sequence | GEPPPGKPADDAGLV (15 residues, linear, no cysteine, no methionine) |
|---|---|
| BPC-157 molecular formula | C62H98N16O22 (PubChem CID 9941957) |
| BPC-157 molecular weight | 1419.5 g/mol (monoisotopic 1418.704) |
| BPC-157 CAS number | 137525-51-0 |
| TB-500 sequence | Ac-LKKTETQ (7 residues, N-terminally acetylated, free C-terminal acid) |
| TB-500 molecular formula | C38H68N10O14 (PubChem CID 62707662) |
| TB-500 molecular weight | 889.0 g/mol (monoisotopic 888.492) |
| TB-500 CAS number | 885340-08-9 |
| Relationship to a parent protein | TB-500 corresponds to residues 17-23 of mature thymosin beta-4 (43 residues, 4963 g/mol, UniProt P62328). BPC-157 is described in its literature as corresponding to a partial sequence of a protein reported in gastric juice. |
| Physical form, solubility, storage | Not established in peer-reviewed literature for either compound. No published measurement of physical form, aqueous solubility in mg/mL, or shelf life was located for either. Supplier specifications are not published data. |
What is the chemical difference between BPC-157 and TB-500?
BPC-157 is a linear pentadecapeptide, GEPPPGKPADDAGLV, with a molecular weight of 1419.5 g/mol. TB-500 is the N-terminally acetylated heptapeptide Ac-LKKTETQ, molecular weight 889.0 g/mol. BPC-157 is therefore roughly 1.6 times the mass of TB-500 and more than twice its length.
Neither peptide contains cysteine or methionine. That removes two common degradation routes for both molecules: disulfide scrambling and methionine oxidation. The distinction matters in one specific comparison. Jean and colleagues showed that oxidizing methionine-6 of full-length thymosin beta-4 to methionine sulfoxide weakened its interaction with G-actin twenty-fold. Methionine-6 sits outside residues 17-23, so the TB-500 fragment does not carry that particular oxidative liability, while the parent protein does.
A second property specific to the parent protein was characterized in 2026. Lachowicz and colleagues published the first experimental description of zinc coordination by full-length thymosin beta-4, identifying discrete Zn(II) adducts at a peptide-to-zinc molar ratio of 1:3 by electrospray mass spectrometry and a sharp aggregation transition at physiological pH, with nuclear magnetic resonance confirming that no folding accompanies the binding. The mechanism they describe runs through progressive neutralization of the strongly negative surface charge of the 43-residue chain. Ac-LKKTETQ carries two lysines against a single glutamate and a free C-terminal acid, which is not that charge profile, and the fragment itself was not tested.
The most consequential difference is not size but provenance. TB-500 corresponds exactly to a defined functional motif inside a well-characterized endogenous protein. Mature thymosin beta-4 is a 43-residue, N-acetylated chain of 4963 g/mol (UniProt P62328), and TB-500 reproduces residues 17-23 of it, about 18 percent of the parent mass. BPC-157 has no such structurally resolved parent motif. Its own literature describes it as corresponding to a partial sequence of a protein reported in gastric juice, and it has carried the development codes PL-10, PLD-116 and PL 14736.
Is TB-500 the same molecule as thymosin beta-4?
No, and this is the most common factual error in secondary coverage of the compound. Esposito and colleagues chemically analyzed TB-500 product material by high-performance liquid chromatography coupled to high-resolution mass spectrometry and identified its content as the N-terminally acetylated 17-23 fragment of thymosin beta-4, then independently synthesized Ac-LKKTETQ by solid-phase peptide synthesis as a confirming reference standard.
The distinction changes how the literature should be read. Most studies commonly cited for TB-500 mechanism used full-length thymosin beta-4 or purified parent protein, not the heptapeptide. Crystallographic work on actin sequestration, alanine-scanning mutagenesis, the cardiac integrin-linked kinase work, and the endothelial migration studies all used the full protein. Findings from those studies describe thymosin beta-4.
The published bridge between the two is the work of Philp and colleagues, who tested native thymosin beta-4 against proteolytic fragments and synthetic peptides and localized the angiogenesis-associated activity in their assays to a seven-amino-acid actin-binding motif. That motif is the region TB-500 reproduces. Peptides missing part of it showed no activity in those assays.
What molecular targets have been studied for each peptide?
Thymosin beta-4, the parent protein of TB-500, has a directly measured molecular target. It binds monomeric G-actin in a 1:1 complex, with a dissociation constant of 2 plus or minus 0.3 micromolar for ATP-G-actin and roughly 100-fold weaker binding to ADP-G-actin. BPC-157, by contrast, has no identified receptor and no published affinity constant for a receptor target.
Irobi and colleagues resolved the structural basis at 2 angstrom resolution using an engineered gelsolin-domain fusion, showing the protein capping both ends of the actin monomer. Jean and colleagues measured an association rate near 1.5 per micromolar per second. Thymosin beta-4 is the prototypical member of the WH2 actin-binding module family, and additional protein-level interactions have been published, including formation of a complex with PINCH and integrin-linked kinase that activates Akt.
That actin interaction has continued to be probed in whole animals rather than only in purified systems. Song and colleagues reported in 2024 that knockout of thymosin beta-4 impaired Mauthner axon regeneration in zebrafish larvae while overexpression promoted it, and attributed the effect in their model to binding of G-actin and promotion of actin polymerization rather than depolymerization. The value of that study for a chemistry comparison is that the in vivo readout is tied back to the same binding event the crystallography and stopped-flow work characterized.
For BPC-157 there is still no identified receptor. Its mechanism literature is pathway-level, built on downstream readouts. The closest receptor-adjacent finding comes from Hsieh and colleagues, who reported up-regulation of VEGFR2 expression together with promotion of VEGFR2 internalization, in association with VEGFR2-Akt-eNOS activation, with the effect blocked by the endocytosis inhibitor dynasore. Other reported pathway associations include FAK-paxillin adhesion signaling in tendon fibroblast migration, ERK1/2 with downstream c-Fos, c-Jun and Egr-1 in endothelial cells, and growth hormone receptor up-regulation in rat tendon fibroblasts.
One 2026 result narrows the gap without closing it. Jelinska and colleagues reported the first cell-free inhibition constants published for BPC-157, measuring it against acetylcholinesterase in a modified Ellman assay with Lineweaver-Burk analysis. BPC-157 gave an inhibition constant of 0.48 millimolar and an IC50 of 2.80 millimolar, and two rationally designed hybrid analogs built from a BPC-157 fragment and an arginine-containing C-terminal extension were somewhat more potent. All three raised the Michaelis-Menten constant while leaving maximum velocity unchanged, which the authors read as reversible competition at the catalytic site. Two qualifications belong with that number. A Ki against an enzyme is a different quantity from a dissociation constant for a binding partner, and 0.48 millimolar is more than two hundred-fold weaker in absolute terms than the 2 micromolar figure measured for thymosin beta-4 and G-actin. The authors themselves note potency far below acetylcholinesterase inhibitors already in clinical use.
The honest summary of this asymmetry is methodological. One compound has a resolved molecular target with measured affinity constants. The other has pathway-level associations without an identified binding partner. That describes the state of each evidence base, and says nothing about which molecule is more useful in any application.
How do the two evidence bases differ in study design?
The thymosin beta-4 literature is weighted toward cell-free structural biology and biophysics: X-ray crystallography, stopped-flow kinetics, alanine-scanning mutagenesis, and circular dichroism folding studies. Its cell-based work spans mainstream models including human umbilical vein endothelial cells, corneal epithelial cells, and cardiomyocytes, published by multiple independent groups across journals including Nature, EMBO Journal and FASEB Journal. That cell-free line is still being extended: the 2026 zinc coordination study combined zeta potential measurement, dynamic light scattering, electrospray mass spectrometry, nuclear magnetic resonance and scanning electron microscopy with elemental mapping on the purified protein, with no cell or animal model involved at any stage.
The BPC-157 literature contains essentially no cell-free structural biology. It is predominantly rodent in vivo work supported by a smaller set of cell-based mechanistic studies in rat tendon fibroblasts, endothelial cells, Caco-2 and HEK293 lines. A large share of the in vivo corpus originates from a single research group in Zagreb, using a characteristic paired-level design comparing two widely separated amounts, 10 micrograms per kilogram against 10 nanograms per kilogram, alongside nitric oxide synthase probes. The 2026 acetylcholinesterase kinetics work is a partial exception, being purified-enzyme biochemistry rather than a pathway readout, and it comes from an independent group in Warsaw.
Experiments that place both peptides in the same design are close to absent. Bicer and colleagues published one in 2026: a four-group rat Achilles tendon transection model, 32 animals, comparing control against BPC-157, TB-500, and the two combined over four weeks. Maximum load to failure was higher in both single-peptide groups than in controls and reached statistical significance in the TB-500 group, histopathological scores were lower in the TB-500 and combined groups, and the combination produced no additional effect over either peptide alone. It is one exploratory study in one model system, and it is the only direct comparison of the two located in the literature.
Both observations are descriptive statements about source diversity and method distribution in the published record. McGuire and colleagues in 2025 and Mateescu and colleagues in 2026 both note that only a small number of pilot human studies of BPC-157 exist, that no pharmaceutical-grade formulation has been developed or validated, and that the compound should be regarded as investigational.
How is each peptide characterized analytically?
Both compounds have their most rigorous analytical characterization from anti-doping laboratories rather than from pharmaceutical development programs, which is an unusual and worth noting feature of this literature.
For BPC-157, Tian and colleagues applied ultra-high-performance liquid chromatography with high-resolution mass spectrometry and 13C/15N stable-isotope labeling for nontargeted metabolite profiling, identifying nine metabolites, eight arising from conventional amide-bond cleavage and one from a novel route. Reported detection limits were 0.01 to 0.11 nanograms per milliliter in human urine, with quantitative linearity across 0.02 to 50 nanograms per milliliter at an R-squared above 0.999.
For TB-500, identity was established by HPLC coupled to high-resolution mass spectrometry on an Orbitrap instrument against a synthesized Ac-LKKTETQ reference standard. A separate equine matrix method using solid-phase extraction on ion-exchange cartridges followed by LC-MS reported limits of 0.02 nanograms per milliliter in plasma and 0.01 nanograms per milliliter in urine.
A 2026 method from Mazzarino and colleagues is the first located that measures both compounds under identical conditions. Their harmonized workflow covers 54 prohibited peptidic and non-peptidic compounds, BPC-157 and TB-500 among them, across dried blood spots, serum and plasma, using a single microextraction step with 500 microliters of methanol and water at 8:2 followed by liquid chromatography with high-resolution mass spectrometry. Reported detection limits were 0.05 to 1.25 nanograms per milliliter, with matrix effects of 5 to 33 percent, extraction yields of 15 to 80 percent, and extract stability of at least 72 hours in the autosampler at 10 degrees Celsius. For a comparison article this matters more than either compound's individual method, because it removes the usual confound of two different laboratories, instruments and matrices.
Summary of published research
Findings below are reported as published by the cited authors, in the model systems they used. They describe laboratory research, and none of them characterize use in humans.
Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Testing and Analysis (2012)
- Model system
- Analytical and synthetic chemistry; product material, synthetic reference standard, plasma and urine matrices
- Conditions
- HPLC with high-resolution mass spectrometry (Orbitrap Exactive); solid-phase peptide synthesis of the reference standard
- Reported finding
- The N-terminally acetylated 17-23 fragment of human thymosin beta-4, Ac-LKKTETQ, was detected and identified in TB-500 material, and the same heptapeptide was independently synthesized as a confirming reference standard. This establishes that TB-500 material is the acetylated heptapeptide fragment rather than full-length thymosin beta-4.
Irobi E, Aguda AH, Larsson M, Guerin C, Yin HL, Burtnick LD, Blanchoin L, Robinson RC. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO Journal (2004)
- Model system
- Cell-free structural biology; X-ray crystallography of an engineered gelsolin-domain-1 fusion in complex with actin
- Conditions
- 2 angstrom resolution; engineered fusion construct used to stabilize an otherwise weak complex
- Reported finding
- The structure showed thymosin beta-4 sequestering actin by capping both ends of the actin monomer, with exchange of actin between thymosin beta-4 and profilin mediated by a minor overlap in binding sites. The construct sequestered actin monomers, severed actin filaments and acted as a leaky barbed-end cap.
Jean C, Rieger K, Blanchoin L, Carlier MF, Lenfant M, Pantaloni D. Interaction of G-actin with thymosin beta 4 and its variants thymosin beta 9 and thymosin beta met9. Journal of Muscle Research and Cell Motility (1994)
- Model system
- Cell-free biochemistry; purified G-actin and purified beta-thymosins with fluorescence and stopped-flow kinetics
- Conditions
- Physiological ionic conditions; equilibrium affinity plus association and dissociation kinetics
- Reported finding
- Thymosin beta-4 inhibited polymerization of ATP-actin with a dissociation constant of 2 plus or minus 0.3 micromolar. Binding to ADP-G-actin was 100-fold weaker. Oxidation of methionine-6 to methionine sulfoxide weakened the interaction 20-fold. Stopped-flow gave association and dissociation rate constants near 1.5 per micromolar per second and 2 per second.
Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal (2003)
- Model system
- In vitro endothelial cell migration and vessel-sprouting assays using native protein, proteolytic fragments and synthetic peptides
- Conditions
- Comparison of native thymosin beta-4 against fragments and synthetic peptides, with competition by soluble actin
- Reported finding
- A seven-amino-acid actin-binding motif was mapped as essential for angiogenic activity in the migration and sprouting assays used. Peptides missing portions of that motif showed no activity, and soluble actin inhibited the adhesion and sprouting effects observed.
Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (2017)
- Model system
- Chick chorioallantoic membrane assay; rat hind-limb ischemia model; endothelial cells in vitro
- Conditions
- Endothelial tube-formation assay with dynasore blockade of endocytosis
- Reported finding
- BPC-157 increased vessel density in vivo and promoted endothelial tube formation in vitro. The reported mechanism was up-regulation of VEGFR2 expression together with promotion of VEGFR2 internalization, in association with VEGFR2-Akt-eNOS activation, and the effect was blocked by dynasore.
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon repair involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology (2011)
- Model system
- Primary rat Achilles tendon fibroblasts and tendon explants (in vitro and ex vivo)
- Conditions
- Explant outgrowth, hydrogen peroxide oxidative-stress survival assay, transwell migration assay
- Reported finding
- BPC-157 accelerated outgrowth from tendon explants and increased cell survival under oxidative stress. In vitro migration of tendon fibroblasts increased in a concentration-dependent manner, attributed by the authors to activation of the FAK-paxillin pathway. Cell proliferation was unchanged.
He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Frontiers in Pharmacology (2022)
- Model system
- Rat and beagle dog in vivo pharmacokinetic study with LC-MS/MS bioanalysis
- Conditions
- LC-MS/MS quantitation across two species
- Reported finding
- Elimination half-life of the parent peptide was under 30 minutes with linear kinetic characteristics. Mean absolute bioavailability was approximately 14 to 19 percent in rats and 45 to 51 percent in beagle dogs. Excretion occurred primarily via urine and bile, with rapid metabolism into peptide fragments.
Tian T, Jing J, Li Y, Wang Y, Deng X, Shan Y. Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of BPC-157 by UHPLC-HRMS. Molecules (2023)
- Model system
- In vitro metabolism plus human urine matrix; analytical chemistry study
- Conditions
- UHPLC-HRMS with 13C/15N isotope-labelled standards; detection limits 0.01 to 0.11 ng/mL; linear range 0.02 to 50 ng/mL
- Reported finding
- Nine metabolites were identified, eight arising from conventional amide-bond cleavage and one via a previously undescribed route. Quantitative linearity was reported at an R-squared above 0.999 across the stated range.
Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature (2004)
- Model system
- Mouse coronary artery ligation model in vivo; embryonic and postnatal cardiomyocytes in vitro
- Conditions
- Cardiomyocyte migration and survival assays alongside the in vivo ligation model
- Reported finding
- Thymosin beta-4 enhanced migration and survival of cardiomyocytes through formation of a complex with PINCH and integrin-linked kinase, which activated Akt. In ligated mice it up-regulated integrin-linked kinase and Akt activity and improved measures of cardiac function.
Au JK, Olivares AO, Henn A, Cao W, Safer D, De La Cruz EM. Widely distributed residues in thymosin beta4 are critical for actin binding. Biochemistry (2008)
- Model system
- Cell-free biochemistry; alanine-scanning mutagenesis against MgATP-actin monomers
- Conditions
- Purified MgATP-actin monomers; alanine point mutants with equilibrium and kinetic measurement
- Reported finding
- Substituting lysine-18 and lysine-19, leucine-28, proline-29 or isoleucine-34 weakened affinity of the actin complex by ten-fold or more, while proline-4 and proline-27 substitutions had little effect. The conserved lysines, which lie inside the LKKTETQ segment, weakened affinity by slowing association and accelerating dissociation.
Mazzarino M, Colpaert T, Deventer K, Van Eenoo P. Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. The Analyst (2026)
- Model system
- Analytical chemistry; dried blood spots, serum and plasma covering 54 prohibited peptidic and non-peptidic compounds including both BPC-157 and TB-500
- Conditions
- Single microextraction step with 500 microliters of methanol/water (8:2, v/v); liquid chromatography with high-resolution mass spectrometry; validation of selectivity, carry-over, matrix effect and extract stability
- Reported finding
- Detection limits were 0.05 to 1.25 nanograms per milliliter, matrix effects 5 to 33 percent, extraction yields 15 to 80 percent, and extracts were stable at least 72 hours in the autosampler at 10 degrees Celsius. All compounds varied by less than 15 percent over at least two months at minus 20 degrees Celsius in every blood matrix. At 4 and 22 degrees Celsius, BPC-157 and TB-500 showed complete degradation only in serum, while in dried matrices all compounds remained detectable throughout the study. This is the first located method that characterizes both peptides under identical conditions.
Jelinska J, Jozwiak M, Szeleszczuk L, Sikora K, Kamysz W, Kleczkowska P, Gackowski M, Grodner B. BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. International Journal of Molecular Sciences (2026)
- Model system
- Cell-free enzyme kinetics; purified acetylcholinesterase with BPC-157 and two designed hybrid analogs, CIARA-1 and CIARA-2
- Conditions
- Modified Ellman assay with Lineweaver-Burk analysis; molecular modeling used as a cross-check on the ranking
- Reported finding
- All three compounds inhibited acetylcholinesterase by a reversible competitive mechanism, raising the Michaelis-Menten constant while leaving maximum velocity unchanged. BPC-157 gave an inhibition constant of 0.48 millimolar and an IC50 of 2.80 millimolar; CIARA-1 gave Ki 0.24 millimolar and IC50 2.52 millimolar, CIARA-2 Ki 0.29 millimolar and IC50 2.73 millimolar. These are the first cell-free inhibition constants published for BPC-157. The authors note potency far below acetylcholinesterase inhibitors already in clinical use.
Lachowicz JI, Congiu T, Salis A, Cesare Marincola F. Zinc Coordination by Thymosin beta4: Structural Determinants and Functional Implications. International Journal of Molecular Sciences (2026)
- Model system
- Cell-free biophysics and coordination chemistry; purified full-length thymosin beta-4 with Zn(II) at physiological pH
- Conditions
- Zeta potential analysis, dynamic light scattering, electrospray ionization mass spectrometry, nuclear magnetic resonance, and scanning electron microscopy with elemental mapping
- Reported finding
- First experimental demonstration that thymosin beta-4 forms discrete Zn(II) adducts and undergoes zinc-induced aggregation at physiological pH. Zn(II) binding progressively neutralized the negative surface charge and triggered a sharp aggregation transition. Mass spectrometry identified complexes at a peptide-to-zinc molar ratio of 1:3, and nuclear magnetic resonance confirmed no folding accompanies binding. Comparing the critical aggregation concentration with physiological extracellular zinc ranges, the authors concluded aggregation is unlikely in plasma or basal interstitial conditions and may become feasible only in zinc-rich microdomains where transient Zn(II) exceeds about 1 micromolar.
Bicer O, Adanir O, Guleryuz Y, Balci EC, Dincel YM, Yenigun MY, Aydin C, Bayrak BY. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery (2026)
- Model system
- Rat Achilles tendon transection and repair model; 32 male Sprague-Dawley rats in four groups
- Conditions
- Control, BPC-157 alone, TB-500 alone, and the two combined, over four weeks; biomechanical load-to-failure testing, Bonar and Movin histopathological scoring, Sirius red polarization, and collagen type III immunohistochemistry
- Reported finding
- Maximum load to failure was higher in the BPC-157 and TB-500 groups than in controls, reaching statistical significance in the TB-500 group. Bonar scores were significantly lower in the TB-500 group and Movin scores lower in the TB-500 and combined groups. Sirius red analysis showed increased type I collagen organization in the peptide groups. The combination produced no additional effect over either peptide alone. The authors describe the study as exploratory. This is the only located experiment placing both peptides in a single design.
Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, Ilie AC, Folescu R, Popa MD, Iurciuc S, Muresan CO, Enache A. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics (2026)
- Model system
- Formulation-science and development review of the published BPC-157 record
- Conditions
- Review of physicochemical properties, pharmacokinetics, formulation barriers across routes, and regulatory position
- Reported finding
- After three decades of preclinical work there is no approved formulation, no validated regimen and no completed Phase II trial. The review records a plasma half-life under 30 minutes against reported biological effects lasting hours to days, and notes that available human data derive from fewer than 30 subjects across three uncontrolled pilot studies. It reports unusual gastric stability, no published solubility profiling across physiologically relevant pH, and no permeability or excipient-compatibility characterization. The authors identify the primary barrier as the absence of fundamental pharmaceutical science rather than absence of biological activity.
McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine (2025)
- Model system
- Narrative review of the preclinical and human BPC-157 literature
- Conditions
- Review of reported pathway mechanisms alongside the human study record
- Reported finding
- The review describes reported activity through pathways including VEGFR2 and nitric oxide synthesis, and counts only three human pilot studies in the published record. Its stated conclusion is that until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and it identifies the gap between animal research and human validation as the central problem.
Song Z, Han A, Hu B. Thymosin beta4 promotes zebrafish Mauthner axon regeneration by facilitating actin polymerization through binding to G-actin. BMC Biology (2024)
- Model system
- Zebrafish larvae Mauthner cell injury model in vivo, with knockout and overexpression
- Conditions
- Single-cell axon injury with regeneration length measurement and behavioral readout
- Reported finding
- Knockout of thymosin beta-4 impaired Mauthner axon regeneration while overexpression promoted it. The authors attributed the effect to binding of G-actin and promotion of actin polymerization rather than depolymerization, and reported restoration of rapid escape behavior in overexpressing larvae. The study ties an in vivo readout to the same G-actin binding event characterized in the cell-free structural and kinetic work.
What laboratory handling data exists for each peptide?
Less than is commonly assumed for either peptide. No peer-reviewed measurement of physical form, aqueous solubility in mg/mL, storage temperature or shelf life was located for BPC-157 or for TB-500. Storage figures on supplier pages are supplier specifications rather than published data, and belong on a certificate of analysis.
Mateescu and colleagues, in a 2026 formulation-science review of BPC-157 in Pharmaceutics, state explicitly that no formal solubility profiling across physiologically relevant pH values has been published, that no pharmaceutical-grade formulation has been developed or validated, and that the compound lacks permeability characterization and formal excipient-compatibility studies. That review counts fewer than 30 human subjects across three uncontrolled pilot studies, and names the absence of characterized formulations and validated pharmacokinetics, rather than any absence of measured biological activity, as the primary development barrier.
What the literature does establish is stability behavior. BPC-157 is described in its primary literature as a stable gastric pentadecapeptide, and the 2026 review reports that it survives exposure to gastric conditions at pH 1 to 2 with pepsin, unlike most peptides, proposing conformational rigidity from the N-terminal polyproline II helix as the structural explanation. That is consistent with the proline block at positions 3 to 5 of its sequence. Degradation in vivo is proteolytic, consistent with the nine amide-cleavage metabolites identified analytically.
For TB-500, N-terminal acetylation removes the free alpha-amino group, a recognized route to reduced aminopeptidase susceptibility, and the acetylated form is confirmed as what the material contains. Detection of the compound and its metabolites in equine plasma and urine in a published anti-doping study indicates in vivo metabolic processing. No published forced-degradation study was located for either peptide.
The one directly comparable stability dataset covering both compounds comes from the 2026 Mazzarino workflow, and it is matrix stability in blood rather than shelf life of isolated material. Every compound in that 54-analyte panel, BPC-157 and TB-500 included, varied by less than 15 percent over at least two months at minus 20 degrees Celsius in all blood matrices tested. At 4 and 22 degrees Celsius the two peptides degraded completely in serum, while in dried matrices all compounds in the panel remained detectable for the full duration of the study. Those observations describe behavior in biological matrices under defined temperatures. They are not a substitute for a formal solubility or shelf-life study of either peptide, which for both compounds remains unpublished.
Frequently asked research questions
Which peptide has better-characterized chemistry?
TB-500, by a clear margin, and specifically because of its parent protein. Thymosin beta-4 has a crystallographically resolved interaction with G-actin, a measured dissociation constant of 2 micromolar, published association and dissociation kinetics, mutagenesis mapping of the residues that matter, and as of 2026 a characterized zinc coordination chemistry. BPC-157 has no identified receptor and no cell-free structural work. Its first published cell-free inhibition constants appeared in 2026, against acetylcholinesterase at millimolar potency, which is a measured interaction with an enzyme rather than an identified receptor.
Has any published study compared the two peptides in the same experiment?
One was located. Bicer and colleagues published a 2026 rat Achilles tendon transection model with four groups across 32 animals: control, BPC-157, TB-500, and both peptides together, over four weeks. Maximum load to failure was higher in both single-peptide groups than in controls and reached statistical significance in the TB-500 group, histopathological scores were lower in the TB-500 and combined groups, and the combination produced no additional effect over either peptide alone. It is a single exploratory study in one model system and the authors describe it as such.
Can findings for thymosin beta-4 be applied to TB-500?
Not automatically. TB-500 is a seven-residue fragment of a 43-residue protein, and most of the widely cited mechanism studies used the full protein. The one study that directly addresses this compared native protein against fragments and synthetic peptides and localized the angiogenesis-associated activity in its assays to the actin-binding motif that TB-500 reproduces.
Why do both compounds appear in anti-doping literature?
Both have been of interest to anti-doping laboratories, which is why the most rigorous analytical characterization of each comes from that field. That work produced the mass-spectrometry identity confirmation for TB-500 material and the nontargeted metabolite profiling for BPC-157, both of which are useful references for identity and purity work.
What is the regulatory status of these compounds?
Neither is an approved product. Published reviews describe BPC-157 as investigational, noting a small number of pilot human studies, no validated formulation, and no completed Phase II trial. TB-500 appears in the literature primarily as a substance of anti-doping interest. Both are supplied for laboratory research only.
BPC-157 and TB-500 at TWO+DOS
TWO+DOS supplies BPC-157 and TB-500 as a research-use-only compound, third-party tested, with certificates of analysis emailed immediately on request.
View the Wolverine Blend (BPC-157 + TB500)listing →Related research overviews
References
- PubChem CID 9941957 (BPC-157): formula, mass and identifier record
- PubChem CID 62707662 (Ac-LKKTETQ): formula, mass and identifier record
- PubChem CID 45382195 (thymosin beta-4, mature 43-residue chain)
- UniProt P62328 (TMSB4X, human thymosin beta-4)
- Esposito et al. 2012, Drug Testing and Analysis (PMID 22962027)
- Irobi et al. 2004, EMBO Journal (PMID 15329672)
- Jean et al. 1994, J Muscle Res Cell Motil (PMID 7929793)
- Philp et al. 2003, FASEB Journal (PMID 14500546)
- Hsieh et al. 2017, Journal of Molecular Medicine (PMID 27847966)
- He et al. 2022, Frontiers in Pharmacology (PMID 36588717)
- Tian et al. 2023, Molecules (PMID 37959764)
- Sikiric et al. 2006, Inflammopharmacology (PMID 17186181)
- Mateescu et al. 2026, Pharmaceutics: formulation-science review of BPC-157 (PMID 42198317)
- Song et al. 2024, BMC Biology (PMID 39443925)
- McGuire et al. 2025, Current Reviews in Musculoskeletal Medicine (PMID 40789979)
- Lachowicz et al. 2026, International Journal of Molecular Sciences (PMID 41751875)
- Jelinska et al. 2026, International Journal of Molecular Sciences (PMID 42278509)
- Mazzarino et al. 2026, The Analyst (PMID 42328738)
- Bicer et al. 2026, Joint Diseases and Related Surgery (PMID 42542926)
For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic use.